
Toujeo is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of 6 years 1
Prescribing Infomation can be found through the links in the Product Cards at the bottom of the page
Starting and switching patients to a basal insulin
Medical supervision with close metabolic monitoring is recommended during any switch of therapy or initiation of insulin, and in the initial weeks thereafter.
Long acting Insulin Overview
Toujeo Features
.png)
Toujeo® can give your patients sustained glycaemic control when administered once daily in the morning or evening*1

Toujeo® can give your patients flexibility around their injection time to fit in with their daily lives when needed*†1
.png)
The pen that was rated by 97.5% of adult patients as easy to use‡5
How to Order Toujeo?
Presentation |
PIP Code |
Toujeo NHS list price |
Toujeo® SoloSTAR® |
3981354 |
GB: £32.14 NI: £53.57 |
Toujeo® DoubleSTAR® |
4104782 |
GB: £64.27 NI: £64.27 |
Toujeo DoubleStar prefilled pen is recommended for patients requiring at least 20 units per day.
There are two channels through which you can order Toujeo.
Via AAH:
- Community Pharmacy - 0344 561 8899
- Dispensing Doctors - 0344 561 8899
- Hospitals - 0344 561 6699
Via Phoenix:
- 01928 750 500 / 01928 750 750
If you are having any issues in getting stock of Toujeo from the above wholesalers, in that instance please contact Sanofi Customer Service on 0800 854 430 for further support.
More about Toujeo
.jpg)
*1 Becker R, et al. Diabetes Care. 2015;38:637-643;2
*†1 Toujeo® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6938/smpc. [Accessed: July 2025]
- Toujeo® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6938/smpc. [Accessed July 2025].
- Lantus® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2376/smpc. [Accessed July 2025].
- Tresiba® Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/2944/smpc. [Accessed July 2025].
- Levemir ®Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/5536/smpc.[Accessed July 2025].
‡5 Pohlmeier H, et al. J Diabetes Sci Technol.2017:11;263-269
Hypoglycaemia is the most frequent adverse reaction observed in clinical trials conducted with Toujeo®.7 Other common adverse effects are lipohypertrophy and injection site reactions.1
For further information on the safety profile of Toujeo® please consult the Summary of Product Characteristics >
T1DM – Type 1 Diabetes
T2DM – Type 2 Diabetes
MAT-XU-2302426 (v14.0) Date of Preparation: July 2025